Tuesday, 02 March 2021

Waters recognizes Dr Amit Mandal's structural proteomics lab

28 January 2013 | News | By Narayan Kulkarni

Waters recognizes Dr Amit Mandal's structural proteomics lab

Dr Amit Kumar Mandal

Dr Amit Kumar Mandal

Waters Corporation, a global organization that has created business advantages for laboratory-dependent organizations, recognized the research in structural proteomics done at the laboratory of Dr Amit Kumar Mandal, Associate Professor- Molecular Medicine and Clinical Proteomics of St. Johns Research Institute, Bangalore as a 'Center of Innovation'.

Dr Mandal has set up one of the best labs for structural proteomics, which strives to determine clinically important molecules that are associated with human diseases, in the country. The lab at the institute has resources such as high sensitivity analytical instruments made of finest quality that will help to find and identify the molecules in human tissue, blood and plasma.

Mr John Gebler, General Manager of the Waters Centers of Innovation Program said, "The Clinical Proteomics lab of Dr Amit Mandal is the only lab in India, which has got the recognition from Waters Corporation. In the Asia Pacific region this lab is the second one to get this recognition, the first being the Department of Biological Sciences at National University of Singapore headed by Assistant Prof Ganesh Anand."

Dr Amit Kumar Mandal joins 19 other researchers and research centers globally recognized by Waters' Centers of Innovation Program. The leading scientists, in partnership with Waters, are using liquid chromatography and mass spectrometry to help shape the future of scientific research and unlock the mysteries of science.

Waters Centers of Innovation Program recognizes and supports the efforts of scientists facilitating breakthroughs in health and life science research, food safety, environmental protection, sports medicine and many other areas.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls